US 12,303,537 B2
Bacteriotherapy for clostridium difficile colitis
Edwin J. Hlavka, Minneapolis, MN (US)
Assigned to Ferring Microbiome Inc., Roseville, MN (US)
Filed by Rebiotix Inc., Roseville, MN (US)
Filed on Aug. 30, 2024, as Appl. No. 18/820,753.
Application 18/820,753 is a continuation of application No. 18/631,959, filed on Apr. 10, 2024, granted, now 12,102,655.
Application 18/631,959 is a continuation of application No. 18/544,083, filed on Dec. 18, 2023, granted, now 11,986,500, issued on May 21, 2024.
Application 18/544,083 is a continuation of application No. 17/886,274, filed on Aug. 11, 2022, granted, now 11,944,654, issued on Apr. 2, 2024.
Application 17/886,274 is a continuation of application No. 15/964,228, filed on Apr. 27, 2018, granted, now 11,446,337, issued on Sep. 20, 2022.
Application 15/964,228 is a continuation of application No. 15/251,725, filed on Aug. 30, 2016, abandoned.
Application 15/251,725 is a continuation of application No. 14/093,913, filed on Dec. 2, 2013, granted, now 9,463,208, issued on Oct. 11, 2016.
Application 14/093,913 is a continuation of application No. 13/576,573, granted, now 9,629,881, issued on Apr. 25, 2017, previously published as PCT/US2011/000184, filed on Feb. 1, 2011.
Claims priority of provisional application 61/351,184, filed on Jun. 3, 2010.
Claims priority of provisional application 61/337,283, filed on Feb. 1, 2010.
Prior Publication US 2024/0415899 A1, Dec. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 9/20 (2006.01); A61K 35/74 (2015.01); C12N 1/04 (2006.01); C12N 1/20 (2006.01); G01N 33/569 (2006.01)
CPC A61K 35/741 (2013.01) [A61K 9/20 (2013.01); A61K 35/74 (2013.01); C12N 1/04 (2013.01); C12N 1/20 (2013.01); G01N 33/56911 (2013.01); G01N 2333/33 (2013.01); G01N 2800/52 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An oral composition, comprising:
a processed fecal sample obtained from a human donor; and
glycerol.